Ginette 35: Comprehensive Hormonal Therapy for PCOS and Acne
| Product dosage: 2.035mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 42 | $1.62 | $67.94 (0%) | 🛒 Add to cart |
| 63 | $1.52 | $101.91 $95.46 (6%) | 🛒 Add to cart |
| 84 | $1.45 | $135.88 $122.12 (10%) | 🛒 Add to cart |
| 126 | $1.41 | $203.82 $178.02 (13%) | 🛒 Add to cart |
| 168 | $1.38
Best per pill | $271.76 $231.34 (15%) | 🛒 Add to cart |
Synonyms | |||
Ginette 35 is a combined oral contraceptive pill containing cyproterone acetate and ethinylestradiol, specifically formulated for the management of moderate to severe acne and hirsutism in women of reproductive age, particularly when associated with polycystic ovary syndrome (PCOS) or other androgen-sensitive conditions. It functions through anti-androgenic, progestogenic, and estrogenic activity to regulate hormonal imbalances, suppress sebum production, and restore ovulatory cycles. Prescribed under medical supervision, it offers a dual benefit of effective dermatological treatment and reliable contraception, making it a cornerstone in endocrine therapy for appropriate patient populations.
Features
- Contains 2 mg cyproterone acetate and 0.035 mg ethinylestradiol per tablet
- 21-day active pill regimen followed by a 7-day hormone-free interval
- Anti-androgenic, progestogenic, and estrogenic pharmacological profile
- Packaged in calendarized blister packs for adherence
- Requires prescription and medical supervision
- Not indicated for contraception alone
Benefits
- Effectively reduces sebum production and improves moderate to severe acne lesions
- Diminishes unwanted facial and body hair (hirsutism) through androgen suppression
- Regulates menstrual cycles and reduces symptoms of hyperandrogenism in PCOS
- Provides reliable contraception when taken as directed
- May improve lipid profiles and reduce ovarian cyst formation in certain patients
- Offers a structured, cyclic dosing regimen to support long-term treatment adherence
Common use
Ginette 35 is primarily prescribed for women experiencing moderate to severe acne that has not responded to topical treatments or oral antibiotics, especially when related to hormonal imbalances. It is also indicated for the treatment of hirsutism and as part of the management strategy for polycystic ovary syndrome (PCOS), where hyperandrogenism plays a key role. It is not intended for use as a general contraceptive without these accompanying indications, and treatment should be initiated only after thorough endocrine evaluation.
Dosage and direction
Take one tablet daily at approximately the same time each day for 21 consecutive days, followed by a 7-day tablet-free interval. Menstruation usually occurs during this break. Begin the next pack on the 8th day, regardless of whether bleeding has stopped. Treatment typically continues for several months, with dermatological and endocrine reassessment every 3–6 months. Initiation should align with menstrual cycle timing under physician guidance—often starting on day 1 of menstruation.
Precautions
- Not for use during pregnancy or lactation
- Requires assessment of cardiovascular risk factors before and during therapy
- Monitor liver function, blood pressure, glucose tolerance, and lipid levels periodically
- Caution in patients with a history of depression, migraine with aura, or thromboembolic disorders
- May affect carbohydrate metabolism; diabetic patients should be monitored closely
- Discontinue 4–6 weeks before elective surgery or periods of prolonged immobilization
Contraindications
- History of venous or arterial thrombosis
- Severe hepatic disease, liver tumors, or jaundice
- Known or suspected hormone-dependent malignancies
- Undiagnosed abnormal genital bleeding
- Hypersensitivity to any component
- Pregnancy, suspected pregnancy, or breastfeeding
- Migraine with focal neurological symptoms
Possible side effects
Common side effects may include nausea, headache, breast tenderness, mood changes, and breakthrough bleeding, especially during initial cycles. Less frequently, weight changes, decreased libido, chloasma, or contact lens intolerance may occur. Rare but serious risks include venous thromboembolism, stroke, myocardial infarction, hepatic adenomas, gallbladder disease, and hypertension. Any unusual or severe symptoms should prompt immediate medical consultation.
Drug interaction
Ginette 35 may interact with enzyme-inducing drugs such as rifampicin, phenytoin, or St. John’s wort, reducing contraceptive efficacy. Broad-spectrum antibiotics like ampicillin or tetracycline may also impair effectiveness. Concurrent use with other hormonal therapies or diabetes medications may require dose adjustments. Always inform prescribers of all concomitant medications, including over-the-counter and herbal products.
Missed dose
If a tablet is missed within 12 hours of the usual time, take it immediately and continue the schedule normally. If missed by more than 12 hours, refer to the patient information leaflet for detailed instructions based on the cycle week. Use additional barrier contraception for 7 days if pills are missed in the first week of a new pack. Multiple missed doses may reduce efficacy and increase breakthrough bleeding.
Overdose
Symptoms of overdose may include nausea, vomiting, and withdrawal bleeding. There is no specific antidote; treatment should be symptomatic and supportive. Serious complications are unlikely due to the hormone content, but medical assessment is advised, especially in pediatric accidental ingestion.
Storage
Store below 25°C in the original packaging, protected from light and moisture. Keep out of reach of children. Do not use after the expiration date printed on the packaging.
Disclaimer
This information is intended for medical professionals and patients under treatment and does not replace personalized medical advice. Ginette 35 is a prescription medication and should be used only under the supervision of a qualified healthcare provider. Individual response and risk profiles vary—always follow your physician’s guidance.
Reviews
Clinical studies and long-term use support the efficacy of Ginette 35 in reducing acne and hirsutism in hyperandrogenic women. Patients often report significant dermatological improvement within 3–6 months, though individual responses vary. Medical professionals emphasize the importance of patient selection, monitoring, and awareness of contraindications to maximize benefits and minimize risks.